VJHemOnc is committed to improving our service to you

SOHO 2020 | Novel antibodies in AML

VJHemOnc is committed to improving our service to you

Marion Subklewe

Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, outlines novel antibody-based immunotherapies developed for the treatment of acute myeloid leukemia (AML), as well as challenges with implementing these agents. Prof. Subklewe also discusses the development of gemtuzumab, the only antibody-drug conjugate approved for the treatment of AML as well as checkpoint inhibitors such as nivolumab, that have been investigated in monotherapy and combination in this indication. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter